

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Commentary

## Lack of type 1 diabetes involvement in SARS-COV-2 population: Only a particular coincidence?



Dario Pitocco<sup>a,\*</sup>, Linda Tartaglione<sup>a</sup>, Luca Viti<sup>a</sup>, Mauro Di Leo<sup>a</sup>, Andrea Manto<sup>a</sup>, Salvatore Caputo<sup>a</sup>, Alfredo Pontecorvi<sup>b</sup>

<sup>a</sup> Diabetes Care Unit, Fondazione Policlinico A.Gemelli IRCCS, Rome, Italy <sup>b</sup> Department of Endocrinology, Fondazione Policlinico A.Gemelli IRCCS, Rome, Italy

In 1591 Italian subjects affected by SARS-COV-2, there was a prevalence of 17% of type 2 diabetes [1]. In analogy to what has been shown in a Chinese population [2] and in another group of Italian subjects [3], surprisingly no cases with type 1 diabetes are apparently reported. This observation needs to be confirmed and further evaluated, for example in regions with high prevalence of the disease (Scandinavian, Finland or Sardinian), but there could be a number of reasons that justify a low incidence of SARS-COV-2 in subjects with type 1 diabetes. This result may be apparently linked to the younger age of type 1 diabetes subjects and the lower prevalence of the disease, if compared to type 2 diabetes in general population, but it could have some intriguing implications. Type 1 diabetes subjects, initially classified as a high-risk category in some countries as Italy, might have taken advantage of an early application of social distancing measures, such as smart working, indirectly supporting this kind of approach to reduce the prevalence and the negative outcomes of the infection. At the same time, from a pathophysiologycal point of view, type 1 diabetes is an autoimmune disorder characterized by a dysregulation of adaptative immunity with an overexpression of CD8+ T lymphocytes [4]. It is conceivable that this immunological attitude might play a protective role during SARS-COV2 infection, in which CD8+ T lymphocytes show an increased apoptosis resulting in lymphocytopenia. Indeed, we cannot rule out that there are some asymptomatic subjects with SARS-COV-2 infection in type 1 diabetic population. Finally, while the infected population has a high prevalence of hypertension, type 1 diabetes is often characterized by hyperglycemia in the absence of the other cardiovascular risk

factors. It could mean and suggest that the metabolic disturbance per se is unrelated to the outcomes of this viral infection.

## Author contribution

All the authors have made substantive contributions to the article and assume full responsibility for its content.

## Funding

The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## **Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

<sup>\*</sup> Corresponding author.

E-mail address: dario.pitocco@policlinicogemelli.it (D. Pitocco). https://doi.org/10.1016/j.diabres.2020.108220

<sup>0168-8227/© 2020</sup> Elsevier B.V. All rights reserved.

<sup>[1]</sup> Grasselli Giacomo, Zangrillo Alberto, Zanella Alberto, Antonelli Massimo, Cabrini Luca, Castelli Antonio, Cereda Danilo, Coluccello Antonio, Foti Giuseppe, Fumagalli Roberto, Iotti Giorgio, Latronico Nicola, Lorini Luca, Merler Stefano, Natalini Giuseppe, Piatti Alessandra, Ranieri Marco Vito, Scandroglio Anna Mara, Storti Enrico, Cecconi Maurizio,

Pesenti Antonio. Baseline characteristics and outcomes of 1591 patients infected With SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323(16):1574. <u>https://doi.org/10.1001/jama.2020.5394</u>.

- [2] Wu Z, McGoogan. Characteristic of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020. <u>https:// doi.org/10.1001/jama.2020.2648</u>.
- [3] Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020;43(6):867–9. <u>https://doi.org/10.1007/ s40618-020-01236-2</u>.
- [4] Pitocco D, Di Leo M, Tartaglione L, De Leva F, Petruzziello C, Saviano A, et al. The role of gut microbiota in mediating obesity and diabetes mellitus. Eur Rev Med Pharmacol Sci 2020;24(3):1548–62.